MannKind logo

MannKind

MNKD | NASDAQ
Chart Builder DCF Calculator
$3.96
-$0.17 (-4.12%)
At close: Nov 16, 2026, 4:00 PM ET
$3.96
$0.00 (0.00%)
After-hours: Nov 16, 2026, 7:30 PM ET
-4.12%

Rating

Updated: Nov 14, 2026
37.3
Fundamentals Weak
Market Sentiment Neutral
Moat None
Sector Rank #591/1021 (Top 58%)

Key Statistics

Market Data

Market Cap $1.27B
1D Range
3.90 4.13
52W Range
2.28 6.21

Valuation (TTM)

PE -17.22
PB -34.14
EV/EBITDA 232.99

Valuation (NTM)

Forward PE 2,414.03
Forward PEG 0.09
Price Target $10.00
Loading financial charts...

Profile

MannKind Corporation operates as a biopharmaceutical firm, primarily focused on innovating and bringing to market respiratory-delivered treatments. Its efforts are directed towards tackling endocrine ...

Sector Healthcare
Industry Biotechnology
Employees 592
IPO Date Jul 28, 2004
Fiscal Year January - December

Latest News

MannKind's ReadyFlow Launch Keeps The Bull Case Alive

5 days ago · seekingalpha.com

MannKind's ReadyFlow Launch Keeps The Bull Case Alive
MannKind Corporation (MNKD) Q3 2026 Earnings Call Transcript

11 days ago · seekingalpha.com

MannKind Corporation (MNKD) Q3 2026 Earnings Call Transcript
MannKind Q3 Earnings Call Highlights

11 days ago · marketbeat.com

MannKind Q3 Earnings Call Highlights
Compared to Estimates, MannKind (MNKD) Q3 Earnings: A Look at Key Metrics

11 days ago · zacks.com

Compared to Estimates, MannKind (MNKD) Q3 Earnings: A Look at Key Metrics
MannKind (MNKD) Reports Q3 Loss, Misses Revenue Estimates

11 days ago · zacks.com

MannKind (MNKD) Reports Q3 Loss, Misses Revenue Estimates
MannKind to Report Third Quarter Financial Results and Host Conference Call on November 5, 2026

18 days ago · globenewswire.com

MannKind to Report Third Quarter Financial Results and Host Conference Call on November 5, 2026
MannKind Data at HFSA 2026 Highlights New Evidence Supporting Furoscix ReadyFlow™ for the Outpatient Management of Edema in Heart Failure (HF) and Chronic Kidney Disease (CKD)

1 month ago · globenewswire.com

MannKind Data at HFSA 2026 Highlights New Evidence Supporting Furoscix ReadyFlow™ for the Outpatient Management of Edema in Heart Failure (HF) and Chronic Kidney Disease (CKD)
MannKind Sees Early ReadyFlow Demand as Pediatric Afrezza Launch Gains Momentum

2 months ago · marketbeat.com

MannKind Sees Early ReadyFlow Demand as Pediatric Afrezza Launch Gains Momentum
MannKind and Rose Pharma Inc Enter Licensing and Collaboration Agreement to Develop an Inhaled Rapid-Acting, Short-Duration GLP-1 for Weight Management

2 months ago · globenewswire.com

MannKind and Rose Pharma Inc Enter Licensing and Collaboration Agreement to Develop an Inhaled Rapid-Acting, Short-Duration GLP-1 for Weight Management
MannKind to Present at Upcoming Investor Conferences

3 months ago · globenewswire.com

MannKind to Present at Upcoming Investor Conferences

Earnings

Latest Earnings
Nov 5, 2026
EPS
-$0.01
Beat +84.75%
REV
$101.87M
Miss -4.82%
Next Earnings
Feb 25, 2027
EPS Est
Pro
Rev Est
Pro
Earnings Details ➞

Analyst Summary

# of Analysts
8
Consensus
Buy
Price Target
$10.00
Upside
+152.53%
Buy (7)
Hold (1)
Sell (0)
Analyst Details ➞

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.